Cargando…

Expression of wild-type and mutated TP53 in breast carcinomas

Detalles Bibliográficos
Autores principales:	Baumbusch, LO, Myhre, S, Langerød, A, Bergamaschi, A, Johnsen, H, Geisler, S, Lønning, PE, Børresen-Dale, A-L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233598/ http://dx.doi.org/10.1186/bcr1177

Ejemplares similares

TP53 mutations among molecular subtypes of HER2-positive tumors
por: Helland, Å, et al.
Publicado: (2005)

Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters
por: Baumbusch, Lars O, et al.
Publicado: (2006)

Evaluation of the arrayed primer extension resequencing assay for TP53 mutation detection
por: Due, EU, et al.
Publicado: (2005)

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer
por: Langerød, A, et al.
Publicado: (2005)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients
por: Olivier, M, et al.
Publicado: (2005)

TP53 and additional pathways in therapy resistance
por: Lønning, PE
Publicado: (2005)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
por: Langerød, Anita, et al.
Publicado: (2007)

Characterization of extracellular matrix composition in breast carcinoma
por: Bergamaschi, A, et al.
Publicado: (2005)

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
por: Holstege, Henne, et al.
Publicado: (2010)

Mapping the location of recurring amplicons in array-CGH data
por: Lingjærde, OC, et al.
Publicado: (2005)

Comparison of methods for pharmacogenomics: SNaPshot, SNPstream UHT, Nanogen, and RFLP
por: Alnæs, GIG, et al.
Publicado: (2005)

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
por: Joshi, H, et al.
Publicado: (2012)

Subclassification and molecular characterization of early stage breast carcinomas using Applied Biosystems Human Genome Survey Microarrays
por: Wang, Y, et al.
Publicado: (2005)

Screening breast cancer patients for Norwegian ATM mutations
por: Laake, K, et al.
Publicado: (2000)

P1264: HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY
por: Husby, S., et al.
Publicado: (2022)

TP53 allele loss, mutations and expression in malignant melanoma.
por: Flørenes, V. A., et al.
Publicado: (1994)

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.
por: Ellis, P. A., et al.
Publicado: (1997)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
por: Andersen, TI, et al.
Publicado: (2000)

TP53 gene mutations and protein accumulation in primary vaginal carcinomas.
por: Skomedal, H., et al.
Publicado: (1995)

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
por: Pietersen, Alexandra M, et al.
Publicado: (2008)

Clinical trials in breast cancer; do we have the right approaches?
por: Lønning, PE
Publicado: (2000)

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
por: Wang, Y, et al.
Publicado: (2004)

Lessons from TP53 mutations in breast cancers: from carcinogen fingerprints to clinical correlates
por: Hainaut, P, et al.
Publicado: (2000)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

Investigation of ATM, TP53 and MDM2 polymorphisms and their association with outcome of radiotherapy for prostate cancer
por: Cintra, Hellen S, et al.
Publicado: (2013)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Functional characterization of genes involved in the development of breast cancer
por: Gjernes, E, et al.
Publicado: (2005)

Promoter composition predicts gene classes in microarray expression analyses of breast cancer
por: Nordgard, SH, et al.
Publicado: (2005)

p16(INK4A) as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy
por: Geisler, S, et al.
Publicado: (2000)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
por: Helland, A., et al.
Publicado: (1998)

Mutant p53 exerts its gain of function through activation of the NF-κB pathway
por: Damalas, A, et al.
Publicado: (2005)

Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.
por: Zelada-Hedman, M., et al.
Publicado: (1997)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

High frequency of complex TP53 mutations in CNS metastases from breast cancer
por: Lo Nigro, C, et al.
Publicado: (2012)

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
por: Kringen, Pedro, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_6ncf0bse0b53ems0bf256e8ufr